Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Active, not recruiting · NCT05230810 · Registry updated 2026-03-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | HER2-positive Metastatic Breast Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-16 | NCT05230810 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Criterium, Inc. | 5 |
| Novartis | 114 |
| Seagen Inc. | 31 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Care & Hematology-Fort Collins | Fort Collins | United States | 1 |
| Louisiana State University Health Sciences Center | New Orleans | United States | 10 |
| University of Colorado Cancer Center | Aurora | United States | 63 |
| University of Wisconsin Carbone Cancer Center | Madison | United States | 58 |